Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents
- 26 October 2004
- journal article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 32 (6) , 959-961
- https://doi.org/10.1042/bst0320959
Abstract
PARP [poly(ADP-ribose) polymerase] activity is up-regulated by binding to DNA strand breaks and its association with DNA repair is well documented. Many anticancer therapies work by inducing breaks in DNA, if unrepaired these can lead to cell death. As PARP promotes DNA repair there is a strong rational to suggest that its inhibition may increase the efficiency of certain cytotoxic treatments. This review discusses the advances made in PARP inhibitor design and the mechanism by which they enhance anti-tumour therapies.Keywords
This publication has 14 references indexed in Scilit:
- Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient CellsClinical Cancer Research, 2004
- Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361JNCI Journal of the National Cancer Institute, 2004
- Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombinationNucleic Acids Research, 2003
- Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitorsPharmacological Research, 2002
- DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells11Edited by J. KarnJournal of Molecular Biology, 2001
- The world according to PARPTrends in Biochemical Sciences, 2001
- Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1Nucleic Acids Research, 2000
- Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?Mutation Research/DNA Repair, 2000
- Mismatch repair and drug responses in cancerDrug Resistance Updates, 1999
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsPublished by Elsevier ,1997